ArticleFrontiers in immunology2022

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.

Qian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.